Sponsors
Together, let's contribute to reduce diagnostic delay in rare diseases!
Legal manufacturer
- Pre-diagnostic tool to support diagnosis and medical decision related to a medical case
- 350 urgent diseases pre-diagnosis to help you to decide to go to the emergency in the right situation,
- 450 common diseases pre-diagnosis to save time during (tele)consultations.
- Software as Medical Device class I in Europe under the regulation MDD 93/42/CEE
- Certification for class II on going under the regulation MDR 2017 745 with the notified body DNV.
- CE Mark
- UDI : (01)03770034 642008(10)1.0
- GMDN nomenclature: 61087 Clinical Management Support Software
- Medical Intelligence Service:
- Address: 9 avenue d'Italie, 75 013 PARIS, France
- VAT number: FR71795177146.
Distributor
- Together, we want to envision a world where everyone can name their disease and have access to innovative therapies.
- We want to continue promoting the best care for these patients:
- Through the diagnoses we accelerate,
- Through the innovations we develop,
- Through the access to appropriate care we promote,
- Through the support we provide to patients and their loved ones.
- For more than 40 years, we are pioneers in science and innovation in rare diseases.
- We are driven by a vocation: to pursue the miracle of science to improve people's lives.
- Join our commitment to unite and shine a light on the rare disease community because together and united, we are stronger.
- Partner of Medvir since 2021 with the funding for the suspected diagnosis of 310 rare diseases.
- In charge of the website www.accelRare.com
Gold sponsors
Sponsors contribute to fund the suspicion of new rare diseases and to promote accelRare to healthcare professionals. Medvir's medical content is developed independently from sponsors.
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
Our motto: making breakthroughs happen. Breakthroughs are more than milestones—they’re moments when hope turns into reality. For decades, Biogen has created medicines for hard-to-treat diseases, particularly in neurology. Scientific curiosity and aspirations to help people around the world are at the core of our legacy and our vision for the future. Our core therapeutic areas are rare diseases, neurology and immunology.
Since 2026, Biogen has partnered with Medvir and co-promotes accelRare with Sanofi.